Clinical Features and Treatment of Systemic JIA in Children

Sponsor
Sohag University
Study ID
NCT07814963
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab (Actemra®) — DRUG
    Tocilizumab used as part of routine clinical care for the management of systemic juvenile idiopathic arthritis. The treatment regimen, duration, and clinical response will be documented according to the treating physician's clinical practice.

Study Details

This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA). The study will include children younger than 18 years who meet the established classification criteria for sJIA. Clinical findings, laboratory investigations, disease activity, complications, and treatments received will be assessed. Participants will be followed prospectively to evaluate their clinical course and response to different therapeutic approaches. The study will help improve understanding of sJIA in children and provide information about the outcomes associated with different treatment modalities.

Key Dates

First listed
Sep 11, 2026
Start date
Oct 1, 2026
Status verified
Sep 2026
Primary completion
Sep 1, 2027
Completion
Sep 1, 2027

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Disease Activity in Children with Systemic Juvenile Idiopathic Arthritis [ Time Frame: At baseline and at 1, 3, 6, 9, and 12 months after treatment initiation. ]

Central Contacts

Related Studies